The use of supplemental oxygen does not improve outcomes in patients with myocardial infarction without hypoxaemia, according to results of the registry-based DETO2X-SWEDEHEART trial. A total of 6,629 patients with suspected myocardial infarction and oxygen saturation ≥90% were randomly allocated to supplemental oxygen (6 l/min for 6–12 h, delivered through an open face mask) or ambient air. Hypoxaemia developed in 1.9% of the oxygen group compared with 7.7% of the ambient-air group. No significant differences were observed in the 1-year rate of all-cause death (5.0% vs 5.1%) or rehospitalization with myocardial infarction (3.8% vs 3.3%). “Supplemental oxygen provides no benefit to patients with acute coronary syndromes who do not have hypoxaemia,” summarizes Joseph Loscalzo in an editorial. “It is clearly time for clinical practice to change to reflect this definitive evidence.”
References
Hofmann, R. et al. Oxygen therapy in suspected acute myocardial infarction. N. Engl. J. Med. http://dx.doi.org/10.1056/NEJMoa1706222 (2017)
Rights and permissions
About this article
Cite this article
Lim, G. Supplemental oxygen in myocardial infarction. Nat Rev Cardiol 14, 632 (2017). https://doi.org/10.1038/nrcardio.2017.143
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrcardio.2017.143
This article is cited by
-
Dynamic predictions of postoperative complications from explainable, uncertainty-aware, and multi-task deep neural networks
Scientific Reports (2023)
-
LncRNA XIST facilitates hypoxia-induced myocardial cell injury through targeting miR-191-5p/TRAF3 axis
Molecular and Cellular Biochemistry (2022)